EMA to compare 'significant benefit' criterion for orphan drugs with HTA standard
This article was originally published in SRA
Executive Summary
The European Medicines Agency will be comparing whether the criterion it uses to evaluate whether an orphan drug has a "significant benefit" over existing treatments is lower or different to that used by health technology assessment (HTA) bodies in the EU.